Pacira Pharm Inc (PCRX): Congress and insider trades
Who in Congress and inside the company traded PCRX, when each filing appeared, and what buying after each one would have earned against the S&P 500.
Key Facts
- Pacira Pharm Inc (PCRX) is a listed stock on NASDAQ.
- 1 member of Congress filed 4 buys and 0 sells of PCRX, the latest published 2021-08-27 (27 August 2021).
- Insiders filed 0 open market buys worth $0 and 9 sells worth $1.2M, the latest filed 2026-08-18 (18 August 2026).
- Across 4 scored buys, Congress averaged -16.2% against the S&P 500 (SPY) over the 90 days after disclosure, with 0% of them ahead of the index. That result is too few trades to draw a conclusion.
- Data as of 2026-09-29 (29 September 2026).
Congress trades in PCRX
as of 2021-08-27| Filed | Member | Type | Size | Days to file | 90 day vs S&P |
|---|---|---|---|---|---|
| 27 Aug 2021 | Tomasz Malinowski (D-NJ) | buy | 1K–15K | 213 | -14.4% |
| 24 Jun 2021 | Tomasz Malinowski (D-NJ) | buy | 1K–15K | 48 | -12.9% |
| 13 Jun 2021 | Tomasz Malinowski (D-NJ) | buy | 1K–15K | 53 | -12.8% |
| 6 Mar 2021 | Tomasz Malinowski (D-NJ) | buy | 1K–15K | 123 | -24.7% |
Nothing matches that search.
Insider trades in PCRX
as of 2026-08-18| Filed | Insider | Type | Shares | Price | Value | 90 day vs S&P |
|---|---|---|---|---|---|---|
| 18 Aug 2026 | SLONIN JONATHAN | sell | 3,040 | $23.23 | $70.6K | n/a |
| 12 Jun 2026 | RIKER LAUREN | sell | 6,115 | $23.50 | $144K | n/a |
| 5 Jun 2026 | WILLIAMS KRISTEN | sell | 10,259 | $22.27 | $228K | n/a |
| 24 Apr 2026 | Cross Shawn | sell | 12,941 | $25.16 | $326K | n/a |
| 22 Apr 2026 | Cross Shawn | sell | 7,714 | $25.14 | $194K | n/a |
| 22 Apr 2026 | Cross Shawn | sell | 1,500 | $25.01 | $37.5K | n/a |
| 22 Apr 2026 | Cross Shawn | sell | 2,845 | $25.01 | $71.2K | n/a |
| 19 Mar 2026 | Froimson Mark | sell | 500 | $21.81 | $10.9K | n/a |
| 19 Mar 2026 | SLONIN JONATHAN | sell | 3,261 | $22.82 | $74.4K | n/a |
Nothing matches that search.
Related pages
Frequently asked questions
Who has bought PCRX?
4 Congress buys by 1 member and 0 insider buys are on file. The tables on this page list every one.
Did buying PCRX after a disclosure beat the market?
Across 4 scored buys, Congress averaged -16.2% against the S&P 500 (SPY) over the 90 days after disclosure, with 0% of them ahead of the index. That result is too few trades to draw a conclusion. A single stock is a small sample.
Sources: Congressional trades: STOCK Act disclosures, collected from CapitolTrades. Insider trades: SEC Form 4 filings, collected from Finviz. Prices: Yahoo Finance daily adjusted closes. Data as of 2026-09-29 (29 September 2026). About these sources.
Not investment advice. Past disclosed trades do not predict future returns. Disclosures are published late, so the trades shown are ones you could only have copied after the fact. Talk to a licensed adviser before you invest.